Abecma denied as duplicate or overlapping therapy by Humana?

Humana's specific coverage criteria for abecma are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Abecma as Duplicate Therapy

Abecma (idecabtagene vicleucel) is a CAR-T cell therapy approved by the FDA for relapsed or refractory multiple myeloma. A duplicate-therapy denial from Humana in this context usually arises when the patient is simultaneously receiving, or has recently completed, another CAR-T therapy or another anti-BCMA agent — such as a bispecific antibody or an antibody-drug conjugate that targets the same receptor. Humana's rationale is that sequential or concurrent BCMA-directed therapies represent redundant mechanisms of action. This denial is worth appealing carefully because the clinical appropriateness of sequencing BCMA-directed agents is an active area of oncology practice and the treating oncologist is in the best position to justify the choice.

## Why This Denial Is Frequently Overturned

The treating oncologist's clinical judgment about sequencing is central here. Abecma is a distinct therapeutic modality (a one-time cellular therapy) with a different mechanism, administration setting, toxicity profile, and durability profile than other anti-BCMA agents. A prescriber letter explaining why the prior or concurrent agent does not render Abecma redundant — and why Abecma is medically necessary for this patient at this point in the treatment course — is the core of a successful appeal.

## Federal Appeal Rights

ACA Section 2719 provides free external review by an Independent Review Organization after internal Humana appeals are exhausted. ERISA Section 503 applies to self-funded employer plans. The external-review window is approximately four months from final internal denial. Given the urgency typical in relapsed/refractory myeloma, request the expedited review track immediately.

## Documentation to Gather

• Oncologist's medical-necessity and anti-redundancy letter: Explains why Abecma is not duplicative of the prior or concurrent therapy — addressing mechanism, clinical goals, and this patient's specific disease status.
• Complete treatment history: A chronological list of all prior myeloma lines, including anti-BCMA therapies, with dates, responses, and reasons for discontinuation.
• Current disease status: Recent lab values and imaging confirming relapsed/refractory status — consult the FDA-approved prescribing label and Humana's published coverage policy for the specific criteria your documentation must address.
• Humana's coverage policy: Download Humana's current published medical policy for Abecma/idecabtagene vicleucel. Copy each criterion and map it to a chart document.
• NCCN guideline reference: The treating oncologist's letter should reference the applicable NCCN guideline category for Abecma in the context of this patient's prior treatment history without quoting specific statistics.

## Appeal Structure

1. Obtain the denial letter's specific duplicate-therapy rationale and the coverage policy version cited. 2. Draft a prescriber rebuttal addressing each stated basis. 3. Use the criteria-mapping format: requirement → chart evidence. 4. Request expedited internal appeal given disease urgency. 5. File for external review immediately after final internal denial.